Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.
Identifieur interne : 000097 ( PubMed/Corpus ); précédent : 000096; suivant : 000098Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.
Auteurs : Irina Isakova-Sivak ; J Rgen De Jonge ; Tatiana Smolonogina ; Andrey Rekstin ; Geert Van Amerongen ; Harry Van Dijken ; Justin Mouthaan ; Paul Roholl ; Victoria Kuznetsova ; Elena Doroshenko ; Vadim Tsvetnitsky ; Larisa RudenkoSource :
- PloS one [ 1932-6203 ] ; 2014.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Drug Evaluation, Preclinical, Female, Ferrets, Gene Expression, Hemagglutinins, Viral (genetics), Hemagglutinins, Viral (immunology), Humans, Immunization, Influenza A Virus, H2N2 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Lung (drug effects), Lung (immunology), Lung (virology), Mice, Mice, Inbred CBA, Neuraminidase (genetics), Neuraminidase (immunology), Nose (drug effects), Nose (immunology), Nose (virology), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (virology), Pandemics (prevention & control), Reassortant Viruses (genetics), Reassortant Viruses (immunology), Vaccines, Attenuated, Virus Replication.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , genetics : Hemagglutinins, Viral, Influenza Vaccines, Neuraminidase.
- chemical , immunology : Hemagglutinins, Viral, Influenza Vaccines, Neuraminidase.
- drug effects : Lung, Nose.
- genetics : Reassortant Viruses.
- immunology : Influenza A Virus, H2N2 Subtype, Lung, Nose, Orthomyxoviridae Infections, Reassortant Viruses.
- prevention & control : Orthomyxoviridae Infections, Pandemics.
- virology : Lung, Nose, Orthomyxoviridae Infections.
- Animals, Drug Evaluation, Preclinical, Female, Ferrets, Gene Expression, Humans, Immunization, Mice, Mice, Inbred CBA, Vaccines, Attenuated, Virus Replication.
Abstract
H2N2 Influenza A caused the Asian flu pandemic in 1957, circulated for more than 10 years and disappeared from the human population after 1968. Given that people born after 1968 are naïve to H2N2, that the virus still circulates in wild birds and that this influenza subtype has a proven pandemic track record, H2N2 is regarded as a potential pandemic threat. To prepare for an H2N2 pandemic, here we developed and tested in mice and ferrets two live attenuated influenza vaccines based on the haemagglutinins of the two different H2N2 lineages that circulated at the end of the cycle, using the well characterized A/Leningrad/134/17/57 (H2N2) master donor virus as the backbone. The vaccine strains containing the HA and NA of A/California/1/66 (clade 1) or A/Tokyo/3/67 (clade 2) showed a temperature sensitive and cold adapted phenotype and a reduced reproduction that was limited to the respiratory tract of mice, suggesting that the vaccines may be safe for use in humans. Both vaccine strains induced haemagglutination inhibition titers in mice. Vaccination abolished virus replication in the nose and lung and protected mice from weight loss after homologous and heterologous challenge with the respective donor wild type strains. In ferrets, the live attenuated vaccines induced high virus neutralizing, haemagglutination and neuraminidase inhibition titers, however; the vaccine based on the A/California/1/66 wt virus induced higher homologous and better cross-reactive antibody responses than the A/Tokyo/3/67 based vaccine. In line with this observation, was the higher virus reduction observed in the throat and nose of ferrets vaccinated with this vaccine after challenge with either of the wild type donor viruses. Moreover, both vaccines clearly reduced the infection-induced rhinitis observed in placebo-vaccinated ferrets. The results favor the vaccine based on the A/California/1/66 isolate, which will be evaluated in a clinical study.
DOI: 10.1371/journal.pone.0102339
PubMed: 25058039
Links to Exploration step
pubmed:25058039Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.</title><author><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="De Jonge, J Rgen" sort="De Jonge, J Rgen" uniqKey="De Jonge J" first="J Rgen" last="De Jonge">J Rgen De Jonge</name><affiliation><nlm:affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Smolonogina, Tatiana" sort="Smolonogina, Tatiana" uniqKey="Smolonogina T" first="Tatiana" last="Smolonogina">Tatiana Smolonogina</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Rekstin, Andrey" sort="Rekstin, Andrey" uniqKey="Rekstin A" first="Andrey" last="Rekstin">Andrey Rekstin</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Van Amerongen, Geert" sort="Van Amerongen, Geert" uniqKey="Van Amerongen G" first="Geert" last="Van Amerongen">Geert Van Amerongen</name><affiliation><nlm:affiliation>Animal Research Center, InTraVacc, Bilthoven, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Van Dijken, Harry" sort="Van Dijken, Harry" uniqKey="Van Dijken H" first="Harry" last="Van Dijken">Harry Van Dijken</name><affiliation><nlm:affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mouthaan, Justin" sort="Mouthaan, Justin" uniqKey="Mouthaan J" first="Justin" last="Mouthaan">Justin Mouthaan</name><affiliation><nlm:affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Roholl, Paul" sort="Roholl, Paul" uniqKey="Roholl P" first="Paul" last="Roholl">Paul Roholl</name><affiliation><nlm:affiliation>Microscope Consultancy, Weesp, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Kuznetsova, Victoria" sort="Kuznetsova, Victoria" uniqKey="Kuznetsova V" first="Victoria" last="Kuznetsova">Victoria Kuznetsova</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Doroshenko, Elena" sort="Doroshenko, Elena" uniqKey="Doroshenko E" first="Elena" last="Doroshenko">Elena Doroshenko</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Tsvetnitsky, Vadim" sort="Tsvetnitsky, Vadim" uniqKey="Tsvetnitsky V" first="Vadim" last="Tsvetnitsky">Vadim Tsvetnitsky</name><affiliation><nlm:affiliation>PATH Vaccine Development Global Program, Seattle, Washington, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25058039</idno><idno type="pmid">25058039</idno><idno type="doi">10.1371/journal.pone.0102339</idno><idno type="wicri:Area/PubMed/Corpus">000097</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000097</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.</title><author><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="De Jonge, J Rgen" sort="De Jonge, J Rgen" uniqKey="De Jonge J" first="J Rgen" last="De Jonge">J Rgen De Jonge</name><affiliation><nlm:affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Smolonogina, Tatiana" sort="Smolonogina, Tatiana" uniqKey="Smolonogina T" first="Tatiana" last="Smolonogina">Tatiana Smolonogina</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Rekstin, Andrey" sort="Rekstin, Andrey" uniqKey="Rekstin A" first="Andrey" last="Rekstin">Andrey Rekstin</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Van Amerongen, Geert" sort="Van Amerongen, Geert" uniqKey="Van Amerongen G" first="Geert" last="Van Amerongen">Geert Van Amerongen</name><affiliation><nlm:affiliation>Animal Research Center, InTraVacc, Bilthoven, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Van Dijken, Harry" sort="Van Dijken, Harry" uniqKey="Van Dijken H" first="Harry" last="Van Dijken">Harry Van Dijken</name><affiliation><nlm:affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mouthaan, Justin" sort="Mouthaan, Justin" uniqKey="Mouthaan J" first="Justin" last="Mouthaan">Justin Mouthaan</name><affiliation><nlm:affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Roholl, Paul" sort="Roholl, Paul" uniqKey="Roholl P" first="Paul" last="Roholl">Paul Roholl</name><affiliation><nlm:affiliation>Microscope Consultancy, Weesp, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Kuznetsova, Victoria" sort="Kuznetsova, Victoria" uniqKey="Kuznetsova V" first="Victoria" last="Kuznetsova">Victoria Kuznetsova</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Doroshenko, Elena" sort="Doroshenko, Elena" uniqKey="Doroshenko E" first="Elena" last="Doroshenko">Elena Doroshenko</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Tsvetnitsky, Vadim" sort="Tsvetnitsky, Vadim" uniqKey="Tsvetnitsky V" first="Vadim" last="Tsvetnitsky">Vadim Tsvetnitsky</name><affiliation><nlm:affiliation>PATH Vaccine Development Global Program, Seattle, Washington, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name><affiliation><nlm:affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Drug Evaluation, Preclinical</term><term>Female</term><term>Ferrets</term><term>Gene Expression</term><term>Hemagglutinins, Viral (genetics)</term><term>Hemagglutinins, Viral (immunology)</term><term>Humans</term><term>Immunization</term><term>Influenza A Virus, H2N2 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (genetics)</term><term>Influenza Vaccines (immunology)</term><term>Lung (drug effects)</term><term>Lung (immunology)</term><term>Lung (virology)</term><term>Mice</term><term>Mice, Inbred CBA</term><term>Neuraminidase (genetics)</term><term>Neuraminidase (immunology)</term><term>Nose (drug effects)</term><term>Nose (immunology)</term><term>Nose (virology)</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Orthomyxoviridae Infections (virology)</term><term>Pandemics (prevention & control)</term><term>Reassortant Viruses (genetics)</term><term>Reassortant Viruses (immunology)</term><term>Vaccines, Attenuated</term><term>Virus Replication</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Hemagglutinins, Viral</term><term>Influenza Vaccines</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hemagglutinins, Viral</term><term>Influenza Vaccines</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lung</term><term>Nose</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Reassortant Viruses</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term><term>Lung</term><term>Nose</term><term>Orthomyxoviridae Infections</term><term>Reassortant Viruses</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term><term>Nose</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Evaluation, Preclinical</term><term>Female</term><term>Ferrets</term><term>Gene Expression</term><term>Humans</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred CBA</term><term>Vaccines, Attenuated</term><term>Virus Replication</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">H2N2 Influenza A caused the Asian flu pandemic in 1957, circulated for more than 10 years and disappeared from the human population after 1968. Given that people born after 1968 are naïve to H2N2, that the virus still circulates in wild birds and that this influenza subtype has a proven pandemic track record, H2N2 is regarded as a potential pandemic threat. To prepare for an H2N2 pandemic, here we developed and tested in mice and ferrets two live attenuated influenza vaccines based on the haemagglutinins of the two different H2N2 lineages that circulated at the end of the cycle, using the well characterized A/Leningrad/134/17/57 (H2N2) master donor virus as the backbone. The vaccine strains containing the HA and NA of A/California/1/66 (clade 1) or A/Tokyo/3/67 (clade 2) showed a temperature sensitive and cold adapted phenotype and a reduced reproduction that was limited to the respiratory tract of mice, suggesting that the vaccines may be safe for use in humans. Both vaccine strains induced haemagglutination inhibition titers in mice. Vaccination abolished virus replication in the nose and lung and protected mice from weight loss after homologous and heterologous challenge with the respective donor wild type strains. In ferrets, the live attenuated vaccines induced high virus neutralizing, haemagglutination and neuraminidase inhibition titers, however; the vaccine based on the A/California/1/66 wt virus induced higher homologous and better cross-reactive antibody responses than the A/Tokyo/3/67 based vaccine. In line with this observation, was the higher virus reduction observed in the throat and nose of ferrets vaccinated with this vaccine after challenge with either of the wild type donor viruses. Moreover, both vaccines clearly reduced the infection-induced rhinitis observed in placebo-vaccinated ferrets. The results favor the vaccine based on the A/California/1/66 isolate, which will be evaluated in a clinical study. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25058039</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.</ArticleTitle><Pagination><MedlinePgn>e102339</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0102339</ELocationID><Abstract><AbstractText>H2N2 Influenza A caused the Asian flu pandemic in 1957, circulated for more than 10 years and disappeared from the human population after 1968. Given that people born after 1968 are naïve to H2N2, that the virus still circulates in wild birds and that this influenza subtype has a proven pandemic track record, H2N2 is regarded as a potential pandemic threat. To prepare for an H2N2 pandemic, here we developed and tested in mice and ferrets two live attenuated influenza vaccines based on the haemagglutinins of the two different H2N2 lineages that circulated at the end of the cycle, using the well characterized A/Leningrad/134/17/57 (H2N2) master donor virus as the backbone. The vaccine strains containing the HA and NA of A/California/1/66 (clade 1) or A/Tokyo/3/67 (clade 2) showed a temperature sensitive and cold adapted phenotype and a reduced reproduction that was limited to the respiratory tract of mice, suggesting that the vaccines may be safe for use in humans. Both vaccine strains induced haemagglutination inhibition titers in mice. Vaccination abolished virus replication in the nose and lung and protected mice from weight loss after homologous and heterologous challenge with the respective donor wild type strains. In ferrets, the live attenuated vaccines induced high virus neutralizing, haemagglutination and neuraminidase inhibition titers, however; the vaccine based on the A/California/1/66 wt virus induced higher homologous and better cross-reactive antibody responses than the A/Tokyo/3/67 based vaccine. In line with this observation, was the higher virus reduction observed in the throat and nose of ferrets vaccinated with this vaccine after challenge with either of the wild type donor viruses. Moreover, both vaccines clearly reduced the infection-induced rhinitis observed in placebo-vaccinated ferrets. The results favor the vaccine based on the A/California/1/66 isolate, which will be evaluated in a clinical study. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Isakova-Sivak</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jonge</LastName><ForeName>Jørgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smolonogina</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rekstin</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Amerongen</LastName><ForeName>Geert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Animal Research Center, InTraVacc, Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dijken</LastName><ForeName>Harry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouthaan</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roholl</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Microscope Consultancy, Weesp, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuznetsova</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doroshenko</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsvetnitsky</LastName><ForeName>Vadim</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>PATH Vaccine Development Global Program, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudenko</LastName><ForeName>Larisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Experimental Medicine, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006389">Hemagglutinins, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006389" MajorTopicYN="N">Hemagglutinins, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008808" MajorTopicYN="N">Mice, Inbred CBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009666" MajorTopicYN="N">Nose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>02</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25058039</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0102339</ArticleId><ArticleId IdType="pii">PONE-D-14-06914</ArticleId><ArticleId IdType="pmc">PMC4109939</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Gen Virol. 1999 Dec;80 ( Pt 12):3167-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10567648</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2013 Dec 5;178(1):78-98</Citation><ArticleIdList><ArticleId IdType="pubmed">23726847</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 Sep;74(18):8502-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10954551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2001 Sep;65(1):171-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11505460</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2001 Dec;146(12):2275-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11811679</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2004 Oct 10;328(1):101-19</Citation><ArticleIdList><ArticleId IdType="pubmed">15380362</ArticleId></ArticleIdList></Reference><Reference><Citation>Vopr Virusol. 1965 Jan-Feb;10(1):67-73</Citation><ArticleIdList><ArticleId IdType="pubmed">5865829</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Virol. 1975 May;19(3):261</Citation><ArticleIdList><ArticleId IdType="pubmed">239585</ArticleId></ArticleIdList></Reference><Reference><Citation>Vopr Virusol. 1977 Jul-Aug;(4):387-95</Citation><ArticleIdList><ArticleId IdType="pubmed">335659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1979 Feb 24;1(8113):439</Citation><ArticleIdList><ArticleId IdType="pubmed">84284</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hyg (Lond). 1985 Oct;95(2):437-45</Citation><ArticleIdList><ArticleId IdType="pubmed">4067298</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1989 Nov;63(11):4603-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2795713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 1990 Dec 31;135(1-2):49-57</Citation><ArticleIdList><ArticleId IdType="pubmed">1703190</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Rev. 1992 Mar;56(1):152-79</Citation><ArticleIdList><ArticleId IdType="pubmed">1579108</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1993;11(3):323-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8447161</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1993 Jun;194(2):781-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7684877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1993 Oct;168(4):881-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8376833</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 1994;135(1-2):101-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8198436</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1994 Nov 15;205(1):17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7975212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull World Health Organ. 1996;74(1):77-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8653819</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1998 Jul;178(1):53-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9652423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1958 Apr 19;1(7025):810-4</Citation><ArticleIdList><ArticleId IdType="pubmed">13526279</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Infect Dis. 2005 Aug;58(4):195-207</Citation><ArticleIdList><ArticleId IdType="pubmed">16116250</ArticleId></ArticleIdList></Reference><Reference><Citation>Glycoconj J. 2006 Feb;23(1-2):93-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16575526</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Nov 10;24(44-46):6588-93</Citation><ArticleIdList><ArticleId IdType="pubmed">17030078</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Nov 17;24(47-48):6859-66</Citation><ArticleIdList><ArticleId IdType="pubmed">17050041</ArticleId></ArticleIdList></Reference><Reference><Citation>Avian Dis. 2007 Mar;51(1 Suppl):425-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17494599</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Nov;3(11):e167</Citation><ArticleIdList><ArticleId IdType="pubmed">17997603</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20949-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18093945</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Genes. 2008 Aug;37(1):16-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18454312</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Apr 28;27(19):2580-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19428864</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2010 Jan;9(1):59-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20021306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Feb;84(4):1715-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20007271</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2010 Mar 1;398(1):109-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20034647</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 May 13;465(7295):161</Citation><ArticleIdList><ArticleId IdType="pubmed">20463719</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Aug;84(15):7695-702</Citation><ArticleIdList><ArticleId IdType="pubmed">20504935</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Mar 10;471(7337):157-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21390107</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Model Mech. 2011 Sep;4(5):575-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21810904</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Nov 15;204(10):1491-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21957153</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2012 Mar;6(2):119-26</Citation><ArticleIdList><ArticleId IdType="pubmed">21819548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 May;86(10):5953-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22438541</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Jan;7(1):66-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22417012</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonsei Med J. 2013 Mar 1;54(2):271-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23364956</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Mar;87(6):3053-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23283953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2013 Aug 15;208(4):594-602</Citation><ArticleIdList><ArticleId IdType="pubmed">23656978</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2000 Sep 15;19(2-3):308-18</Citation><ArticleIdList><ArticleId IdType="pubmed">10930686</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000097 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000097 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25058039
|texte= Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25058039" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |